|
|
|
|
|
|
|
¾àÇ°°Ë»ö |
|
ºÎÀÛ¿ë ¹× ´ëó¹ý |
|
|
|
|
|
|
|
¿¢¼¿·Ðĸ½¶1.5mg(¸®¹Ù½ºÆ¼±×¹ÎŸ¸£Å¸¸£»ê¿°) Exelon Cap. 1.5mg
|
Àü¹®ÀǾàÇ° | ±Þ¿© | ½Å¾à
|
|
¼öÀÔÀǾàÇ°
|
|
|
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàÇ° ÀÎÅÍ³Ý ÆǸŸ¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
Àü¹®/ÀÏ¹Ý |
Àü¹®
|
|
|
ȸ¹é»ö-¿¯Àº Ȳ»öÀÇ °¡·ç°¡ µç »ó, ÇÏ :Ȳ»öÀÇ °æÁúĸ½¶Á¦ |
|
|
|
|
|
Á¦Á¶È¸»ç |
Novartis
|
ÆǸÅȸ»ç |
Çѱ¹³ë¹ÙƼ½º(ÁÖ)
|
Çã°¡Á¤º¸ |
Á¤»ó
(2000.08.31)
|
BIT ¾àÈ¿ºÐ·ù |
Á¤½ÅºÎÈ°¾à (Nootropics & Neurotonics)
|
º¹ÁöºÎºÐ·ù |
119[±âŸÀÇ ÁßÃ߽Űæ¿ë¾à ] |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå |
653600770[E01630611] Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó \1,079 ¿ø/1ĸ½¶(2024.07.01)(ÇöÀç¾à°¡)\1,086 ¿ø/1ĸ½¶(2022.01.01) (º¯°æÀü¾à°¡)
|
|
|
ATCÄÚµå |
Rivastigmine / N06DA03 |
NDCÄÚµå |
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
|
¼ººÐ / ÇÔ·® |
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
|
÷°¡Á¦ |
¹«¼ö±Ô»ê,
¹Ì°áÁ¤¼¿·ê·Î¿À½º,
»êÈö(Ȳ»ö),
»êÈƼź,
½ºÅ׾Ƹ£»ê¸¶±×³×½·,
Á©¶óƾ,
È÷ÇÁ·Î¸á·Î¿À½º
|
|
|
|
|
|
|
|
|
|
Ç× ¸ñ |
³» ¿ë |
|
ºÎÀÛ¿ëºóµµ ¹× ´ëó¹ý |
[À¯·á] |
|
|
|
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-12-03 |
|
|
|
|
|
|
|
|
|